Clinical Trial Update: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating RO7268489 as add-on therapy to ocrelizumab in participants with progressive multiple sclerosis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• RO7268489

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Progressive Multiple Sclerosis | Phase 2 | Status: RECRUITING